Petnet Radiopharmaceutical Solutions Profile
Key Indicators
- Authorised Capital ₹ 24.00 Cr
as on 18-12-2024
- Paid Up Capital ₹ 24.00 Cr
as on 18-12-2024
- Company Age 19 Year, 1 Month
- Last Filing with ROC 30 Sep 2023
- Revenue 13.94%
(FY 2020)
- Profit 17.05%
(FY 2020)
- Ebitda 1.97%
(FY 2020)
- Net Worth 6.79%
(FY 2020)
- Total Assets -0.17%
(FY 2020)
About Petnet Radiopharmaceutical Solutions
The Corporate was formerly known as Dade Behring Diagnostics India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 30 September 2023. It's a company limited by shares with an authorized capital of Rs 24.00 Cr and a paid-up capital of Rs 24.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Petnet Radiopharmaceutical Solutions Private Limited India is Priyanka as COMPANY SECRETARY. Nallur Hariharan and Ajit Damle serve as directors at the Company.
- CIN/LLPIN
U51507MH2005PTC309308
- Company No.
309308
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Nov 2005
- Date of AGM
29 Mar 2024
- Date of Balance Sheet
30 Sep 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Petnet Radiopharmaceutical Solutions?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Priyanka | Company Secretary | 15-Nov-2022 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nallur Hariharan  | Director | 01-Jul-2023 | Current |
| Ajit Damle | Director | 27-Oct-2021 | Current |
Financial Performance and Corporate Structure Insights of Petnet Radiopharmaceutical Solutions.
Petnet Radiopharmaceutical Solutions Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 13.94% increase. The company also saw a substantial improvement in profitability, with a 17.05% increase in profit. The company's net worth moved up by a moderate rise of 6.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Petnet Radiopharmaceutical Solutions?
In 2020, Petnet Radiopharmaceutical Solutions had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Siemens Healthcare Private LimitedActive 9 years 6 monthsNallur Hariharan and Ajit Damle are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Petnet Radiopharmaceutical Solutions?
Unlock and access historical data on people associated with Petnet Radiopharmaceutical Solutions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Petnet Radiopharmaceutical Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Petnet Radiopharmaceutical Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
